Table 1 Correlations between D-dimer and clinicopathologic features of patients

Age

63 (58-69)

64 (58-70)

0.153

Sex (male)

585 (62.63%)

263 (63.07%)

0.878

BMI, kg/m²

22.7 (20.8-24.4)

22.7 (20.3-24.5)

0.467

Platelet, ×10⁹

183 (148-225)

192 (153-247)

0.002

Albumin, g/L

39 (36-42)

39 (36-41)

0.089

Obstructive jaundice

301 (32.23%)

180 (43.17%)

< 0.001

NLR

2.45 (1.87-3.28)

2.71 (2.03-3.76)

0.001

CA19-9, U/mL

137.3 (37.3-387.2)

179.2 (49.0-611.4)

0.005

ASA score

0.915

 1

412 (44.11%)

184 (44.12%)

 2

505 (54.07%)

224 (53.72%)

 3

17 (1.82%)

9 (2.16%)

Comorbidity

 Hypertension

343 (36.72%)

172 (41.25%)

0.114

 Diabetes mellitus

235 (25.16%)

85 (20.38%)

0.056

 Cardiac disease

65 (6.96%)

23 (5.52%)

0.321

Tumor location

0.012

 Head

572 (61.24%)

285 (68.35%)

 Body/tail

362 (38.76%)

132 (31.65%)

Surgical approach

0.086

 Open

706 (75.59%)

333 (79.86%)

 Robotic

228 (24.41%)

84 (20.14%)

 Major vessel resection

136 (14.56%)

55 (13.19%)

0.504

 Neural invasion

798 (85.44%)

357 (85.61%)

0.934

 R1 resection, ≤ 1 mm

114 (12.21%)

64 (15.35%)

0.115

T stage

0.674^a

 T1

159 (17.02%)

64 (15.35%)

 T2

428 (45.82%)

192 (46.04%)

 T3

120 (12.85%)

66 (15.83%)

 T4

227 (24.30%)

95 (22.78%)

N stage

0.521^a

 N0

487 (52.14%)

218 (52.28%)

 N1

360 (38.54%)

142 (34.05%)

 N2

87 (9.31%)

57 (13.67%)

Differentiation

0.014^a

 Well

361 (38.65%)

137 (32.85%)

 Moderate

422 (45.18%)

193 (46.28%)

 Poor

151 (16.17%)

87 (20.86%)

Adjuvant chemotherapy

556 (59.53%)

210 (50.34%)

0.002